Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.58 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8585041 | 0.85 | LMNA (0.51) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL1225868 | 0.82 | TDP1 (0.56) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL5805659 | 0.82 | LMNA (0.49) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL4702232 | 0.80 | LMNA (0.67) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL12928714 | 0.80 | LMNA (0.67) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL30981000 | 0.79 | LMNA (0.61) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL5225651 | 0.79 | LMNA (0.61) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL8283521 | 0.79 | LMNA (0.65) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL19779527 | 0.78 | CNR1 (0.41) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL3276922 | 0.78 | CYP19A1 (0.57) | LMNACYP19A1CYP17A1ALDH1A1PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767690-B2 | Amino alcohol derivatives and their use as renin inhibitor | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
| EP-1725530-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| EP-1711456-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005070870-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058320-A1 | Organic Compounds | REN, AGTR1, ADH1C | LMNA 3013/4885CYP1A2 74/4885CYP3A4 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.